79 related articles for article (PubMed ID: 27405253)
1. Dual blockade of hepatitis C virus entry at a gatekeeper of hepatocytes: Not only a preventive, but also therapeutic target of claudin 1.
Sugiyama M; Kanto T
Hepatology; 2016 Sep; 64(3):979-82. PubMed ID: 27405253
[No Abstract] [Full Text] [Related]
2. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies.
Fofana I; Zona L; Thumann C; Heydmann L; Durand SC; Lupberger J; Blum HE; Pessaux P; Gondeau C; Reynolds GM; McKeating JA; Grunert F; Thompson J; Zeisel MB; Baumert TF
J Virol; 2013 Sep; 87(18):10405-10. PubMed ID: 23864633
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
[TBL] [Abstract][Full Text] [Related]
5. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
7. A master regulator of tight junctions involved in hepatitis C virus entry and pathogenesis.
Denolly S; Cosset FL
Hepatology; 2017 May; 65(5):1756-1758. PubMed ID: 28177536
[No Abstract] [Full Text] [Related]
8. Aspirin inhibits hepatitis C virus entry by downregulating claudin-1.
Yin P; Zhang L
J Viral Hepat; 2016 Jan; 23(1):62-4. PubMed ID: 26289738
[TBL] [Abstract][Full Text] [Related]
9. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
[TBL] [Abstract][Full Text] [Related]
10. COPII cargo claudin-12 promotes hepatitis C virus entry.
Huang J; Yin P; Zhang L
J Viral Hepat; 2019 Feb; 26(2):308-312. PubMed ID: 30339745
[No Abstract] [Full Text] [Related]
11. Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'?
Pécheur EI
Gut; 2014 Jul; 63(7):1035-7. PubMed ID: 24092864
[No Abstract] [Full Text] [Related]
12. Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.
Hashimoto Y; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Ann N Y Acad Sci; 2017 Jun; 1397(1):5-16. PubMed ID: 28415141
[TBL] [Abstract][Full Text] [Related]
13. ["Entry inhibitors" prevent virus access to the cell]].
Fessler B
MMW Fortschr Med; 2015 Mar; 157 Suppl 1():86. PubMed ID: 26012995
[No Abstract] [Full Text] [Related]
14. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
15. [Locked outside: cure of chronic hepatitis C using an entry inhibitor].
Mailly L; Zeisel MB; Baumert TF
Med Sci (Paris); 2015 Dec; 31(12):1075-7. PubMed ID: 26672658
[No Abstract] [Full Text] [Related]
16. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry.
Hsu WC; Chang SP; Lin LC; Li CL; Richardson CD; Lin CC; Lin LT
Antiviral Res; 2015 Jun; 118():139-47. PubMed ID: 25865056
[TBL] [Abstract][Full Text] [Related]
17. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.
Anggakusuma ; Colpitts CC; Schang LM; Rachmawati H; Frentzen A; Pfaender S; Behrendt P; Brown RJ; Bankwitz D; Steinmann J; Ott M; Meuleman P; Rice CM; Ploss A; Pietschmann T; Steinmann E
Gut; 2014 Jul; 63(7):1137-49. PubMed ID: 23903236
[TBL] [Abstract][Full Text] [Related]
18. The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.
Descamps V; Helle F; Louandre C; Martin E; Brochot E; Izquierdo L; Fournier C; Hoffmann TW; Castelain S; Duverlie G; Galmiche A; François C
Antiviral Res; 2015 Jun; 118():93-102. PubMed ID: 25823619
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives.
Nakajima S; Watashi K; Kamisuki S; Tsukuda S; Takemoto K; Matsuda M; Suzuki R; Aizaki H; Sugawara F; Wakita T
Biochem Biophys Res Commun; 2013 Nov; 440(4):515-20. PubMed ID: 24099774
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
